Urologix, Inc.
ULGX · OTC
3/31/2015 | 12/31/2014 | 9/30/2014 | 6/30/2014 | |
|---|---|---|---|---|
| Revenue | $2,796 | $3,079 | $3,021 | $3,294 |
| % Growth | -9.2% | 1.9% | -8.3% | – |
| Cost of Goods Sold | $1,485 | $1,615 | $1,559 | $1,711 |
| Gross Profit | $1,311 | $1,464 | $1,462 | $1,583 |
| % Margin | 46.9% | 47.5% | 48.4% | 48.1% |
| R&D Expenses | $298 | $337 | $334 | $344 |
| G&A Expenses | $449 | $467 | $488 | $526 |
| SG&A Expenses | $1,106 | $1,196 | $1,298 | $1,537 |
| Sales & Mktg Exp. | $657 | $729 | $810 | $1,011 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,464 | $1,598 | $1,703 | $2,060 |
| Operating Income | -$153 | -$134 | -$241 | -$3,408 |
| % Margin | -5.5% | -4.4% | -8% | -103.5% |
| Other Income/Exp. Net | -$196 | -$219 | -$191 | -$179 |
| Pre-Tax Income | -$349 | -$353 | -$432 | -$3,587 |
| Tax Expense | $0 | $4 | $5 | -$62 |
| Net Income | -$349 | -$357 | -$437 | -$3,525 |
| % Margin | -12.5% | -11.6% | -14.5% | -107% |
| EPS | -0.016 | -0.016 | -0.02 | -0.17 |
| % Growth | 2.4% | 19.2% | 88.1% | – |
| EPS Diluted | -0.016 | -0.016 | -0.02 | -0.17 |
| Weighted Avg Shares Out | 21,838 | 21,782 | 21,487 | 21,299 |
| Weighted Avg Shares Out Dil | 21,838 | 21,782 | 21,487 | 21,299 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $190 | $216 | $188 | $177 |
| Depreciation & Amortization | $111 | $116 | $134 | $140 |
| EBITDA | -$42 | -$18 | -$107 | -$247 |
| % Margin | -1.5% | -0.6% | -3.5% | -7.5% |